2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1876

Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant
Abstract Number: 1007

Macrophage Mediators of Autoimmune Valvular Carditis and Fibrosis
Abstract Number: 1362

Magnetic Resonance Imaging Features Can Classify Adults Who Will Develop Accelerated Knee Osteoarthritis
Abstract Number: 2922

Magnetic Resonance Imaging of Sacroiliac Joints in Patients with Osteitis Condensans Ilii Reveals a Typical Pattern of Lesions Relevant for Differential Diagnosis with Axial Spondyloarthritis
Abstract Number: 311

Magnetic Resonance Imaging of the Cervical Spine in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Presenting with Chronic Neck Pain – a Systematic Comparison of Clinical Assessments
Abstract Number: 2862

Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Abstract Number: 2854

Majeed Syndrome Causing LPIN2 mutations May Prevent Bone “Healing” By Rendering M2 Macrophage Proinflammatory
Abstract Number: 2952

Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score
Abstract Number: 558

Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis
Abstract Number: 2483

Major Secular Trends of Patient Characteristics and Inclusion Criteria in RA Clinical Trials
Abstract Number: 1524

Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 2991

Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Abstract Number: 1515

Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim Analysis of All-Case Post-Marketing Surveillance
Abstract Number: 1595

Malignancy in Psoriatic Disease
Abstract Number: 162

Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/racemosa

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].